Comparative Pharmacology
Head-to-head clinical analysis: DYNABAC versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNABAC versus R P MYCIN.
DYNABAC vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dirithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, specifically to the 23S rRNA, inhibiting peptide chain elongation by blocking the translocation step. It also interferes with the assembly of the 50S ribosomal subunit. This action is primarily bacteriostatic but can be bactericidal at higher concentrations.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
500 mg orally once daily or 250 mg orally twice daily; usual duration 5-14 days depending on infection
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults with normal renal function; may extend to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Approximately 65% of a dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; about 15% is excreted unchanged in the bile; fecal elimination accounts for <5%.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic